# EDGAR Filing Document

**Accession Number:** 0002055515
**File Stem:** 0001213900-26-001393
**Filing Date:** 2026-1
**Character Count:** 23773
**Document Hash:** b9bfe5aea36f12c3dd9d72d9d82aaf1e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-001393.hdr.sgml**: 20260105

**ACCESSION NUMBER**: 0001213900-26-001393

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260105

**DATE AS OF CHANGE**: 20260105

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pluri Inc.
- **CENTRAL INDEX KEY:** 0001158780
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980351734
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-78785
- **FILM NUMBER:** 26508866

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** MATAM ADVANCED TECHNOLOGY PARK
- **STREET 2:** BUILDING NO. 5
- **CITY:** HAIFA
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972-74-710-7171

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** MATAM ADVANCED TECHNOLOGY PARK
- **STREET 2:** BUILDING NO. 5
- **CITY:** HAIFA
- **PROVINCE COUNTRY:** L3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PLURISTEM THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20071228

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PLURISTEM LIFE SYSTEMS INC
- **DATE OF NAME CHANGE:** 20030701

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AI SOFTWARE INC
- **DATE OF NAME CHANGE:** 20010906
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chutzpah Holdings Ltd
- **CENTRAL INDEX KEY:** 0002055515

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Y9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 4TH FLOOR, LIBERATION HOUSE
- **STREET 2:** CASTLE STREET
- **CITY:** ST HELIER
- **STATE:** Y9
- **ZIP:** JE1 4HH
- **BUSINESS PHONE:** 44-1534-823126

**MAIL ADDRESS:**
- **STREET 1:** 4TH FLOOR, LIBERATION HOUSE
- **STREET 2:** CASTLE STREET
- **CITY:** ST HELIER
- **STATE:** Y9
- **ZIP:** JE1 4HH

## Exhibit 99.1

**Exhibit 1**

**JOINT FILING AGREEMENT**

This joint filing agreement (this "**Agreement**") is made and entered into by and between Alexandre Weinstein Manieu, Chutzpah Holdings Limited, Chutzpah Holdings LP and Plantae Bioscience Ltd.

The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Form 3, Form 4, Form 5 or Schedule 13D or Schedule 13G, and any and all amendments thereto and any other document relating thereto (collectively, the "**Filings**") required to be filed by them pursuant to the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"). Each party to this Agreement further agrees and covenants to the other parties that it will fully cooperate with such other parties in the preparation and timely filing (and other delivery) of all such Filings.

This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

**IN WITNESS WHEREOF**, the undersigned hereby execute this Joint Filing Agreement as of the 5<sup>th</sup> day of January, 2026.

---

| |
|:---|
| **ALEXANDRE WEINSTEIN MANIEU** |
| /s/ Alexandre Weinstein Manieu |

---

---

| | |
|:---|:---|
| **CHUTZPAH HOLDINGS LIMITED** | **CHUTZPAH HOLDINGS LIMITED** |
| By: | /s/ Ana Ventura |
| Name: | Ana Ventura |
| Title: | Authorized Officer<br> Beaumont (Directors) Limited,<br> Sole Corporate Director |

---

---

| | |
|:---|:---|
| **CHUTZPAH HOLDINGS LIMITED** | **CHUTZPAH HOLDINGS LIMITED** |
| By: | /s/ Karen Oliver |
| Name: | Karen Oliver |
| Title: | Authorized Officer<br> Beaumont (Directors) Limited,<br> Sole Corporate Director |

---

---

| | |
|:---|:---|
| **CHUTZPAH HOLDINGS LP** | **CHUTZPAH HOLDINGS LP** |
| By: | /s/ Alexandre Weinstein |
| Name: | Alexandre Weinstein |
| Title: | Authorized Signatory |

---

---

| | |
|:---|:---|
| **PLANTAE BIOSCIENCE LTD.** | **PLANTAE BIOSCIENCE LTD.** |
| By: | /s/ Eli Mor |
| Name: | Eli Mor |
| Title: | Authorized Signatory |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Pluri Inc.**

*(Name of Issuer)*

**COMMON STOCK, PAR VALUE $0.00001 PER SHARE**

*(Title of Class of Securities)*

**72942G104**

*(CUSIP Number)*

**Chutzpah Holdings Limited**<br>4TH Floor, Liberation House<br>Castle Street<br>St. Helier Jersey Islands Y9 JE1 4HH<br>1-212-613-2091

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/30/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **72942G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Chutzpah Holdings Limited** | Name of reporting person<br>**Chutzpah Holdings Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**Y9** | Citizenship or place of organization<br>**Y9** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2018014.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2018014.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2018014.00** | Aggregate amount beneficially owned by each reporting person<br>**2018014.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**18.93%** | Percent of class represented by amount in Row (11)<br>**18.93%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** 1 Pursuant to the Securities Purchase Agreement dated January 23, 2025 (the "Securities Purchase Agreement"), entered into between Chutzpah Holdings Limited ("CHL") and the Issuer relating to a private placement offering of:  1,383,948 shares of common stock, par value $0.00001 per share of the Issuer (the "Common Shares"), (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 26,030 Common Shares, and (iii) warrants to purchase up to 84,599 Common Shares (the "Common Warrants"). The purchase price for each Common Share is $4.61. The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable at any time following the receipt of certain approvals from the Issuer's shareholders (subsequently received on June 30, 2025), and remain exercisable until exercised in full. The Common Warrants have an exercise price of $5.568 per share and will be exercisable for three years following June 3, 2025.

On March 13, 2025, the Issuer, Pluri Biotech Ltd., a wholly owned subsidiary of the Issuer (the "Pluri Biotech"), entered into a Share Purchase Agreement with CHL and Plantae Bioscience Ltd ("Plantae"), pursuant to which CHL and Plantae: (i) sold to Pluri Biotech, 400,000 ordinary shares and 175,000 preferred seed-1 shares, representing approximately 71.1% of the equity of Kokomodo Ltd.(on a fully diluted basis), an Israeli company ("Kokomodo," and such shares, the "Purchased Interests") and (ii) transferred to Pluri Biotech, a convertible loan, pursuant to an assignment and assumption agreement, reflecting a principal aggregate amount of $0.5 million.  In consideration for the sale, transfer and conveyance of the Purchased Interests, the Issuer paid the Reporting Person an aggregate purchase price of $4.5 million, payable in 976,139 common shares of the Company, which as of January 23, 2025, represented 12.14% of the Issuer's issued and outstanding share capital on a fully diluted basis after the deemed issuance of the above consideration shares.  Of the 976,139 common shares of the Issuer, 452,702 was issued to Plantae and 523,437 was issued to CHL.  CHL owns approximately 78% of Plantae.

On April 25, 2025, the Reporting Person and the Issuer entered into an amendment to the Securities Purchase Agreement, whereby the Company and the Investor agreed to exchange 976,139 of the Common Shares for additional pre-funded warrants to purchase up to 976,139 Common Shares.  The additional pre-funded warrants issued to the Investor have the same terms as the Pre-Funded Warrants issued pursuant to the Securities Purchase Agreement, and as such, they have an exercise price of $0.0001 per share, are exercisable at any time following the receipt of certain approvals from the Company's shareholders, as required by the applicable rules of the Nasdaq Capital Market, and remain exercisable until exercised in full.  have an exercise price of $0.0001 per share, are exercisable at any time following the receipt of certain approvals from the Issuer's shareholders (subsequently received on June 30, 2025), and remain exercisable until exercised in full.  At the time of the exchange, CHL held 931,246 Common Shares (1,383,948 Common Shares plus 523,437 Common Shares minus 976,139 Common Shares exchanged for an equal amount of pre-funded warrants).

On October?29,?2025, pursuant to shareholder approval for the exercise of pre-funded warrants and common warrants at the shareholder meeting held on June 30, 2025, the Reporting Person exercised pre funded warrants to acquire 1,002,169 shares of Common Stock of the Issuer at an exercise price of $0.0001 per share.  The pre funded warrants were originally issued pursuant to the Securities Purchase Agreement dated January?23,?2025, as amended April 25, 2025.  As on date, the Reporting Person holds 2,018,014 Common Shares (931,246 Common Shares plus 1,002,169 Common Shares plus 84,599 unexercised warrants to purchase Common Shares).

2 Indicates the Reporting Person 's ownership of 2,018,014 Common Shares directly held.

3 Calculated on the basis of 2,018,014 Common Shares directly held and 10,661,533 total outstanding shares of the Issuer (calculated on a fully diluted basis which includes 5,643 fully vested shares of stock, and assumes the exercise of Chutzpah Holdings LP's 625,000 common warrants to purchase Common Shares).

| **CUSIP No.** | **72942G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Chutzpah Holdings LP** | Name of reporting person<br>**Chutzpah Holdings LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ONTARIO** | Citizenship or place of organization<br>**ONTARIO** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1250000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1250000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1250000.00** | Aggregate amount beneficially owned by each reporting person<br>**1250000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.72%** | Percent of class represented by amount in Row (11)<br>**11.72%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** 4 On December 8, 2025, the Issuer entered into an additional Securities Purchase Agreement with Chutzpah Holdings LP (the "CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein, ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares, par value $0.00001 per share (the "CHLP Common Shares") of the Company, and (ii) warrants (the "CHLP Common Warrants") to purchase up to 625,000 Common Shares.  The combined purchase price for each CHLP Common Share and CHLP Common Warrant is $4.00.  The CHLP Common Warrants are exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026.  The CHLP Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation.

5 Indicates CHLP's ownership of 1,250,000 Common Shares, assuming exercise of the CHLP Common Warrants in full.

6 Calculated on the basis of: (i) CHLP exercising the CHLP Common Warrants and holding 1,250,000 Common Shares directly; and (ii) 10,661,533 total outstanding shares of the Issuer (calculated on a fully diluted basis which includes Mr. Weinstein's 5,643 fully vested shares of stock).

| **CUSIP No.** | **72942G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Plantae Bioscience Ltd.** | Name of reporting person<br>**Plantae Bioscience Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**452702.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**452702.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**452702.00** | Aggregate amount beneficially owned by each reporting person<br>**452702.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.25%** | Percent of class represented by amount in Row (11)<br>**4.25%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** 7 On March 13, 2025, the Issuer, Pluri Biotech, entered into a Share Purchase Agreement with CHL and Plantae, pursuant to which CHL and Plantae: (i) sold to Pluri Biotech, 400,000 ordinary shares and 175,000 preferred seed-1 shares, representing approximately 71.1% of the equity of Kokomodo (on a fully diluted basis), and (ii) transferred to Pluri Biotech, a convertible loan, pursuant to an assignment and assumption agreement, reflecting a principal aggregate amount of $0.5 million.  In consideration for the sale, transfer and conveyance of the Purchased Interests, the Issuer paid the Reporting Person an aggregate purchase price of $4.5 million, payable in 976,139 common shares of the Company, which as of January 23, 2025, represented 12.14% of the Issuer's issued and outstanding share capital on a fully diluted basis after the deemed issuance of the above consideration shares.  Of the 976,139 common shares of the Issuer, 452,702 was issued to Plantae and 523,437 was issued to CHL.  CHL owns approximately 78% of Plantae.

8 Calculated on the basis of: (i) Plantae's ownership of 452,702 Common Shares; and (ii) 10,661,533 total outstanding shares of the Issuer (calculated on a fully diluted basis).

| **CUSIP No.** | **72942G104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Alexandre Weinstein** | Name of reporting person<br>**Alexandre Weinstein** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**V8** | Citizenship or place of organization<br>**V8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**5643.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5643.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**5643.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5643.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5643.00** | Aggregate amount beneficially owned by each reporting person<br>**5643.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.05%** | Percent of class represented by amount in Row (11)<br>**0.05%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 9 As of the date of this filing, 4,189 RSUs have vested, with 1,281 RSUs (from the 10,250 RSUs grant) to vest on February 25, 2026, and 173 RSUs (from the 519 RSUs grant) to vest on February 28, 2026.  The remaining 5,126 RSUs are unvested and subject to future vesting conditions. Unvested RSUs confer no voting rights or dividend entitlements until settlement into common shares. Additional RSUs will vest thereafter, which may increase Mr. Weinstein's ownership. Mr. Weinstein will amend this Schedule 13D as required by law.
10 See note above.
11 See note above.
12 See note above.
13 See note above.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
COMMON STOCK, PAR VALUE $0.00001 PER SHARE

**(b) Name of Issuer:**
Pluri Inc.

**(c) Address of Issuer's Principal Executive Offices:**
Pluri Biotech Ltd., Matam Park Building 5, Haifa, L3, 3508409

This Amendment No. 3 ("Amendment") supplements the statements made on Schedule 13D of Chutzpah Holdings Limited ("CHL") that was filed with the Securities and Exchange Commission (the "Commission") on February 12, 2025 (the "Original Schedule 13D"), as amended by the following amendments to the Original Schedule 13D: first amendment filed with the Commission on May 12, 2025; second amendment to filed with the Commission on December 15, 2025 (collectively, with the Original Schedule 13D, the "Schedule 13D").  Capitalized terms used but not defined herein have the meanings given to such terms in the Schedule 13D.  This Amendment is being filed for the purpose of publicly disclosing certain important developments in connection with CHL, and certain of its affiliates' investment in Pluri, Inc.  Except as set forth herein, the Schedule 13D is unmodified.

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is hereby amended and restated as follows:

The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and restated as follows:

The information contained on the cover pages of this Schedule 13D is incorporated by reference.

**(b)**
Item 5(b) of the Schedule 13D is hereby amended and restated as follows:

In the aggregate, the Reporting Persons beneficially own 3,726,359 Common Shares representing approximately 35% of the issued and outstanding shares of the Issuer.  Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person.

**(c)**
Item 5(c) of the Schedule 13D is amended and supplemented as follows:

The information contained in Item 4 of this Schedule 13D is incorporated by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Chutzpah Holdings Limited

**Signature:** /s/ Ana Ventura

**Name/Title:** Ana Ventura/Authorized Officer Beaumont (Directors) Limited, sole corporate director

**Date:** 01/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Chutzpah Holdings LP

**Signature:** /s/ Alexandre Weinstein

**Name/Title:** Alexandre Weinstein/Authorized Signatory Chutzpah Holdings LP

**Date:** 01/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Plantae Bioscience Ltd.

**Signature:** /s/ Eli Mor

**Name/Title:** Eli Mor/Authorized Signatory Plantae Bioscience Ltd.

**Date:** 01/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Alexandre Weinstein

**Signature:** /s/ Alexandre Weinstein

**Name/Title:** Alexandre Weinstein

**Date:** 01/05/2026